Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Innovative treatments and technologies for cutaneous lymphoma
Innovative Treatments and Technologies
The Stanford team is commonly involved in testing new cancer treatments not yet available at other facilities. Examples include:
Targeted therapies that attack tumor surface proteins, aberrant epigenetic regulation, signaling or cell survival pathways, or microenvironment
Mogamulizumab (KW-0761) is a bioengineered, humanized monoclonal antibody against CCR4, selectively expressed on tumor cells; the defucosylated technology provides enhanced efficacy
Brentuximab vedotin (SGN-35) is an antibody-drug-conjugate that targets CD30, commonly expressed on tumor cells in cutaneous T-cell lymphomas
Low-dose (12 Gy) total skin electron beam therapy combined with vorinostat, a potentially radiation enhancing agent, to reduce overall toxicity of radiation while improving efficacy
Pralatrexate, as newer anti-folate agent, combined with oral bexarotene demonstrates synergistic efficacy
Novel/newer topical agents including topical histone deacetylase inhibitor
Non-myeloablative allogeneic hematopoietic stem cell transplantation using total skin electron beam therapy, total lymphoid irradiation, and anti-thymocyte globulin as novel preparatory regimen for patients with mycosis fungoides and Sezary syndrome
Newer techniques utilizing rapid molecular diagnostic methods or new immunostains for earlier and more accurate diagnosis
Stanford multispecialty care
The Stanford Multspecialty Cutaneous Lymphoma Clinic (MCLC) is a national leader in clinical/translational research and treatment of patients with cutaneous lymphomas. In operation for over 30 years at Stanford, the MCLC (similar to a tumor board) is held twice weekly and patients are co-evaluated and co-managed by cutaneous, medical, and radiation oncologists, and pathologists who each have expertise in cutaneous lymphoma. Stanford is unique in offering this interdisciplinary care in cutaneous lymphoma to provide the most comprehensive and optimal care for patients with this very rare group of lymphomas.
The Stanford Medicine Online Second Opinion program offers you easy access to our world-class doctors. It’s all done remotely and you don’t have to visit our hospital or one of our clinics for this service. You don’t even need to leave home!
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.